Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
FDA, after delay, clears Regeneron and Sanofi drug for COPD
FDA approves Dupixent for COPD, making it the first biologic medicine for the condition in the U.S. This expansion is expected to boost sales, which reached almost $12 billion globally last year. Dupixent targets Type 2 inflammation in a subset of COPD patients, showing reduced exacerbations and improved lung function in trials. European regulators approved Dupixent for COPD in July, but U.S. approval required additional efficacy data. The approval comes as Regeneron faces market value loss due to a court case, increasing pressure on its pipeline.
FDA Approves Dupilumab (Dupixent) for Treatment of COPD
FDA approves dupilumab (Dupixent) for COPD, based on BOREAS and NOTUS trials, offering reduced exacerbations and improved lung function in patients with type 2 inflammation.
Dupixent approved in the US as the first-ever biologic medicine for patients
Dupixent approved by FDA as first biologic for COPD patients with eosinophilic phenotype, showing significant reduction in exacerbations and improvements in lung function and quality of life in phase 3 studies.
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD
FDA approves Dupixent for chronic obstructive pulmonary disease, based on late-stage trials showing reduced flare-ups and improved breathing in patients with uncontrolled symptoms driven by eosinophils.
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
The article discusses the importance of SSR (Server-Side Rendering) in modern web development for improving performance and SEO.
Dupixent approved in China as the first-ever biologic medicine for patients ...
Dupixent approved in China as the first biologic for COPD, following EU approval. Based on phase 3 studies, Dupixent significantly reduced exacerbations, improved lung function, and quality of life. COPD is a priority in China's Healthy China 2030 plan. Dupixent is now approved in four indications in China.
Dupixent approved in China as the first-ever biologic medicine for patients
Dupixent approved in China for COPD, reducing exacerbations, improving lung function, and enhancing quality of life in phase 3 studies.
© Copyright 2025. All Rights Reserved by MedPath